Advertisement
Screener

ALNYLAM PHARMACEUTICALS, INC. (ALNY) EBITDA

ALNYLAM PHARMACEUTICALS, INC. (ALNY) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income $231.44M; Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA (m); Operating income $367.98M; Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA (m); Operating income -$16.20M; Depreciation and amortization (m).
  • 2025-03-31: Basis Reported; EBITDA (m); Operating income $18.08M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2008-12-31 to 2018-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)$231.44M(m)$1.29B(m)(m)(m)$298.26M$413.13M$347.92M$13.31M
2025-09-30Reported(m)$367.98M(m)$1.25B(m)$12.14M*$351.03M*$197.23M$358.81M$322.08M-$12.12M
2025-06-30Reported(m)-$16.20M(m)$773.69M(m)$14.29M*$127.81M*$142.03M$323.62M$323.31M$30.92M
2025-03-31Reported(m)$18.08M(m)$594.19M(m)$8.97M-$118.31M$70.18M$265.12M$239.95M$15.88M
2024-09-30Reported(m)-$76.91M(m)$500.92M(m)$4.19M*$43.71M*$81.98M$270.93M$220.99M$2.91M
2024-06-30Reported(m)$48.61M(m)$659.83M(m)$8.02M*$124.16M*$67.27M$294.14M$248.40M$5.72M
2024-03-31Reported(m)-$43.44M(m)$494.33M(m)$12.97M-$81.52M$54.61M$261.00M$210.80M$2.35M
2023-09-30Reported(m)$213.87M(m)$750.53M(m)$17.09M*$359.41M*$79.47M$253.18M$199.18M$2.99M
2023-06-30Reported(m)-$229.83M(m)$318.75M(m)$15.92M*-$58.99M*$75.34M$248.53M$214.69M$1.81M
2023-03-31Reported(m)-$149.81M(m)$319.29M(m)$13.89M-$166.47M$41.43M$230.57M$183.66M$1.74M
2022-09-30Reported(m)-$258.04M(m)$264.31M(m)$16.51M*-$115.28M*$36.51M$245.37M$235.86M-$23.00K
2022-06-30Reported(m)-$191.69M(m)$224.82M(m)$16.05M*-$122.82M*$34.04M$205.71M$169.98M$2.73M
2022-03-31Reported(m)-$146.73M(m)$213.26M(m)$17.86M-$171.19M$23.46M$169.89M$154.47M$985.00K
2021-09-30Reported(m)-$181.68M(m)(m)(m)$26.06M*-$134.04M*$28.09M$194.57M$142.07M$278.00K
2021-06-30Reported(m)-$146.16M(m)$220.55M(m)$11.25M*-$121.86M*$30.26M$182.63M$145.32M$1.23M
2021-03-31Reported(m)-$186.25M(m)$177.57M(m)$17.18M-$235.66M$23.02M$185.90M$146.86M$1.02M
2020-09-30Reported(m)-$225.20M(m)$125.85M(m)$12.42M*-$110.33M*$20.83M$161.78M$167.47M$839.00K
2020-06-30Reported(m)-$198.86M(m)$103.96M(m)$16.66M*-$135.33M*$18.27M$155.00M$127.90M$1.33M
2020-03-31Reported(m)-$210.16M(m)$99.48M(m)$19.62M-$246.16M$13.30M$169.57M$126.76M$575.00K
2019-09-30Reported(m)-$216.30M(m)$70.06M(m)$36.06M*-$182.63M*$5.21M$160.80M$120.35M-$394.00K
2019-06-30Reported(m)-$236.27M(m)$44.71M(m)$21.24M*$288.69M*$4.33M$163.89M$112.77M$960.00K
2019-03-31Reported(m)-$188.79M(m)$33.29M(m)$44.05M-$188.51M$3.35M$129.13M$89.61M$695.00K
2018-09-30Reported(m)-$254.56M(m)$2.07M(m)$45.41M*-$153.81M*$137.00K$139.94M$116.55M$445.00K
2018-06-30Reported(m)-$192.35M(m)$29.91M(m)$22.71M*-$102.69M*(m)$137.58M$84.68M$79.00K
2018-03-31Reported-$144.23M(m)(m)(m)(m)$21.26M-$155.66M(m)$96.86M$72.45M-$62.00K
2017-12-31Reported-$143.59M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2017-09-30Reported-$122.21M*-$125.80M$3.59M*$17.10M-714.86%*$25.68M*-$98.36M*(m)$95.25M$47.64M(m)
2017-06-30Reported-$117.41M*-$120.47M$3.07M*$15.93M-736.93%*$21.65M*(m)(m)$90.63M(m)(m)
2017-03-31Reported-$103.51M(m)(m)(m)(m)$36.15M(m)(m)$86.98M(m)(m)
2016-12-31Reported-$112.42M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-09-30Reported-$103.18M*-$106.68M$3.50M*(m)(m)$20.30M*(m)(m)$97.94M(m)(m)
2016-06-30Reported-$88.44M*-$92.45M$4.01M*(m)(m)$21.62M*(m)(m)$83.17M(m)(m)
2016-03-31Reported-$105.43M(m)(m)(m)(m)$2.76M(m)(m)$96.27M(m)(m)
2015-12-31Reported-$87.44M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-09-30Reported-$73.06M*-$78.33M$5.27M*(m)(m)$6.48M*(m)(m)$68.62M(m)(m)
2015-06-30Reported-$67.92M*-$72.94M$5.02M*(m)(m)$1.26M*(m)(m)$67.01M(m)(m)
2015-03-31Reported-$48.53M(m)(m)(m)(m)$2.11M(m)(m)$58.03M(m)(m)
2014-12-31Reported-$42.37M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-09-30Reported-$42.08M*-$45.20M$3.12M*(m)(m)$3.19M*(m)(m)$46.27M(m)(m)
2014-06-30Reported-$42.14M*-$45.01M$2.87M*(m)(m)$1.85M*(m)(m)$44.67M(m)(m)
2014-03-31Reported-$266.46M(m)(m)(m)(m)$388.00K(m)(m)$43.76M(m)(m)
2013-12-31Reported-$26.97M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-09-30Reported-$29.47M*-$32.23M$2.76M*(m)(m)$950.00K*-$21.71M*(m)$34.46M(m)-$2.27M
2013-06-30Reported-$18.60M*-$21.31M$2.71M*(m)(m)$379.00K*-$23.60M*(m)$24.21M(m)-$2.88M
2013-03-31Reported-$7.68M(m)(m)(m)(m)$1.80M-$971.00K(m)$22.18M(m)-$562.00K
2012-12-31Reported-$86.33M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-09-30Reported-$15.86M*-$18.15M$2.29M*(m)(m)$5.73M*$5.21M*(m)$22.09M(m)(m)
2012-06-30Reported-$9.46M*-$12.07M$2.60M*(m)(m)$1.67M*-$21.69M*(m)$21.72M(m)(m)
2012-03-31Reported-$8.77M(m)(m)(m)(m)$263.00K-$30.21M(m)$21.07M(m)(m)
2011-12-31Reported-$12.35M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-09-30Reported-$11.18M*-$12.44M$1.26M*(m)(m)$265.00K*-$29.02M*(m)$24.27M(m)(m)
2011-06-30Reported-$11.83M*-$13.12M$1.29M*(m)(m)$474.00K*-$26.58M*(m)$25.30M(m)(m)
2011-03-31Reported-$14.34M(m)(m)(m)(m)$28.00K-$6.30M(m)$26.35M(m)(m)
2010-12-31Reported-$11.12M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2010-09-30Reported-$7.46M*-$8.73M$1.27M*(m)(m)$1.07M*-$24.04M*(m)$27.47M(m)$298.00K
2010-06-30Reported-$10.40M*-$11.63M$1.22M*(m)(m)$1.43M*-$24.31M*(m)$28.14M(m)-$229.00K
2010-03-31Reported-$10.15M(m)(m)(m)(m)$1.10M-$15.60M(m)$24.70M(m)$18.00K
2009-12-31Reported-$6.93M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2009-09-30Reported-$8.54M*-$9.65M$1.11M*(m)(m)$737.00K*-$20.59M*(m)$23.22M(m)-$552.00K
2009-06-30Reported(m)-$22.41M(m)(m)(m)(m)(m)(m)$38.62M(m)$908.00K

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported(m)$501.58M(m)$3.71B(m)$58.70M$524.08M$677.17M$1.32B$1.21B$9.40M
2024-12-31Reported(m)-$176.88M(m)$2.25B(m)$34.28M-$8.31M$306.51M$1.13B$975.53M-$99.22M
2023-12-31Reported(m)-$282.18M(m)$1.83B(m)$62.21M$104.16M$268.22M$1.00B$795.65M$6.72M
2022-12-31Reported(m)-$785.07M(m)$1.04B(m)$72.06M-$541.27M$140.17M$883.01M$770.66M$4.16M
2021-12-31Reported(m)-$708.65M(m)$844.29M(m)$76.37M-$641.69M$115.00M$792.16M$620.64M$680.00K
2020-12-31Reported(m)-$828.44M(m)$492.85M(m)$70.36M-$614.96M$74.19M$654.82M$588.42M$2.68M
2019-12-31Reported(m)-$939.43M(m)$219.75M(m)$140.16M-$278.43M$25.06M$655.11M$479.00M$863.00K
2018-12-31Reported(m)-$814.67M(m)$74.91M(m)$126.89M-$562.62M$1.80M$505.42M$382.36M$823.00K
2017-12-31Reported-$486.72M(m)(m)(m)(m)$104.21M-$382.79M$0.00$390.63M$199.37M$0.00
2016-12-31Reported-$409.46M(m)(m)(m)(m)$64.56M-$307.70M(m)$382.39M$89.35M$0.00
2015-12-31Reported-$276.96M(m)(m)(m)(m)$12.95M(m)(m)$276.50M(m)$0.00
2014-12-31Reported-$393.05M(m)(m)(m)(m)$8.96M(m)(m)$190.25M(m)-$40.21M
2013-12-31Reported-$82.71M(m)(m)(m)(m)$4.01M-$68.66M(m)$112.96M(m)-$2.69M
2012-12-31Reported-$120.42M(m)(m)(m)(m)$8.35M-$115.61M(m)$86.57M(m)-$10.57M
2011-12-31Reported-$49.69M(m)(m)(m)(m)$1.29M-$87.07M(m)$99.30M(m)$0.00
2010-12-31Reported-$39.13M(m)(m)(m)(m)$4.73M-$84.34M(m)$106.38M(m)$514.00K
2009-12-31Reported-$42.12M(m)(m)(m)(m)$4.95M-$72.14M(m)$108.73M(m)$582.00K
2008-12-31Reported-$22.11M(m)(m)(m)(m)$10.76M$65.49M(m)$96.88M(m)$719.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10